Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Lipoprotein(a): Knowns, unknowns and uncertainties
Massimiliano Ruscica, Cesare R. Sirtori, Alberto Corsini, et al.
Pharmacological Research (2021) Vol. 173, pp. 105812-105812
Closed Access | Times Cited: 69

Showing 26-50 of 69 citing articles:

Long-term tracking and population characteristics of lipoprotein (a) in the Cardiovascular Risk in Young Finns Study
Olli T. Raitakari, Annukka M. Kivelä, Katja Pahkala, et al.
Atherosclerosis (2022) Vol. 356, pp. 18-27
Closed Access | Times Cited: 16
Exploring the role of lipoprotein(a) in cardiovascular diseases and diabetes in Chinese population
Zubair Hussain, Junaid Iqbal, Hongcai Liu, et al.
International Journal of Biological Macromolecules (2023) Vol. 233, pp. 123586-123586
Open Access | Times Cited: 8
PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort
Juan Vicente-Valor, Xandra García‐González, Sara Ibáñez-García, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 146, pp. 112519-112519
Open Access | Times Cited: 20
Efficacy and Safety of Lipid-Lowering Drugs of Different Intensity on Clinical Outcomes: A Systematic Review and Network Meta-Analysis
Wenrui Ma, Qinyuan Pan, Defeng Pan, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 19
Association of Urinary Lead and Cadmium Levels, and Serum Lipids with Subclinical Arteriosclerosis: Evidence from Taiwan
Chien‐Yu Lin, Sandy Huey-Jen Hsu, Ching‐Way Chen, et al.
Nutrients (2023) Vol. 15, Iss. 3, pp. 571-571
Open Access | Times Cited: 7
Examining a decade-long trend in exposure to per- and polyfluoroalkyl substances and their correlation with lipid profiles: Insights from a prospective cohort study on the young Taiwanese population
Chien‐Yu Lin, Sandy Huey-Jen Hsu, Hui‐Ling Lee, et al.
Chemosphere (2024) Vol. 364, pp. 143072-143072
Closed Access | Times Cited: 2
Causal associations between insulin and Lp(a) levels in Caucasian population: a Mendelian randomization study
Mateusz Lejawa, Marcin Goławski, Martyna Fronczek, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Lipoprotein(a) and the atherosclerotic burden – should we wait for clinical trial evidence before taking action?
Isabella Fichtner, Chiara Macchi, Alessandra Stefania Rizzuto, et al.
Atherosclerosis Plus (2024) Vol. 58, pp. 16-23
Open Access | Times Cited: 2
Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia)
Elisa Waldmann, WU Li-ya, Kristina Busygina, et al.
PLoS ONE (2022) Vol. 17, Iss. 3, pp. e0265838-e0265838
Open Access | Times Cited: 11
Lipoprotein (a) is related to In-Stent neoatherosclerosis incidence rate and plaque vulnerability: Optical Coherence Tomography Study
Xiaohang Yuan, Yan Han, Xin Hu, et al.
The International Journal of Cardiovascular Imaging (2022) Vol. 39, Iss. 2, pp. 275-284
Open Access | Times Cited: 10
Oxidized phospholipids and lipoprotein(a): An update
A.-D. Koutsogianni, Evangelos Liberopoulos, Konstantinos Tellis, et al.
European Journal of Clinical Investigation (2021) Vol. 52, Iss. 4
Closed Access | Times Cited: 14
Familial Hypercholesterolemia and Acute Coronary Syndromes: The Microbiota–Immunity Axis in the New Diagnostic and Prognostic Frontiers
Andrea Piccioni, Elena Niccolai, Gloria Rozzi, et al.
Pathogens (2023) Vol. 12, Iss. 4, pp. 627-627
Open Access | Times Cited: 5
Correlation between lipoprotein(a) and recurrent ischemic events post-cerebral vascular stent implantation
Nan Zhang, Kaili Shi, Shuyin Ma, et al.
Journal of Stroke and Cerebrovascular Diseases (2024) Vol. 33, Iss. 11, pp. 107882-107882
Closed Access | Times Cited: 1
Association between lipoprotein (a) and risk of atherosclerotic cardiovascular disease events among maintenance hemodialysis patients in Beijing, China: a single-center, retrospective study
Qiaojing Liang, Guojuan Zhang, Liping Jiang
BMC Nephrology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Apolipoprotein B Modifies the Association between Lipoprotein(a) and ASCVD Risk
Yuhui Lai, Shaozhao Zhang, Yue Leon Guo, et al.
American Heart Journal (2024) Vol. 281, pp. 157-167
Closed Access | Times Cited: 1
Lipoprotein(a) Serum Levels Predict Pulse Wave Velocity in Subjects in Primary Prevention for Cardiovascular Disease with Large Apo(a) Isoforms: Data from the Brisighella Heart Study
Arrigo F.G. Cicero, Federica Fogacci, Giuseppe Derosa, et al.
Biomedicines (2022) Vol. 10, Iss. 3, pp. 656-656
Open Access | Times Cited: 7
Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease
Fei Gao, Yue Ping Li, Xiaoteng Ma, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 7
Long-term fasting: Multi-system adaptations in humans (GENESIS) study–A single-arm interventional trial
Franziska Grundler, Magalie Viallon, Robin Mesnage, et al.
Frontiers in Nutrition (2022) Vol. 9
Open Access | Times Cited: 6
Study on the relationship between lipoprotein (a) and diabetic kidney disease
Anni Wang, Shaojie Zhang, Yayu Li, et al.
Journal of Diabetes and its Complications (2022) Vol. 37, Iss. 1, pp. 108378-108378
Closed Access | Times Cited: 6
Forecasting risk analysis of detection for carotid artery stenosis based on serum levels grading of lipoprotein (a)
O. V. Gaisenok
Health Risk Analysis (2022), Iss. 3, pp. 133-142
Open Access | Times Cited: 5
Impact of lipoprotein(a) level on cardiometabolic disease in the Chinese population: The CHCN‐BTH Study
Juan Xia, Chunyue Guo, Han Cao, et al.
European Journal of Clinical Investigation (2021) Vol. 52, Iss. 2
Closed Access | Times Cited: 7
Lipoprotein a Combined with Fibrinogen as an Independent Predictor of Long-Term Prognosis in Patients with Acute Coronary Syndrome: A Multi-Center Retrospective Study
Cai-Yan Cui, Tao Ye, Lian-Chao Cheng, et al.
Journal of Cardiovascular Development and Disease (2022) Vol. 9, Iss. 10, pp. 322-322
Open Access | Times Cited: 4
Role of lipoprotein(a) in plaque progression
Massimiliano Ruscica, Alessandra Stefania Rizzuto, Alberto Corsini
European Heart Journal Supplements (2022) Vol. 24, Iss. Supplement_I, pp. I72-I75
Open Access | Times Cited: 4
Association between lipoprotein(a) and insulin resistance in Chinese adults: results from the China health and nutrition survey
Heng Wang, Jiali Fan
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 2
Lipoprotein(a) Modulates Carotid Atherosclerosis in Metabolic Syndrome
Anna Laura Cremonini, Andrea Pasta, Federico Carbone, et al.
Frontiers in Molecular Biosciences (2022) Vol. 9
Open Access | Times Cited: 3

Scroll to top